Literature DB >> 852494

Plasma concentrations of propranolol in patients with essential hypertension.

A Lehtonen, J Kanto, T Kleimola.   

Abstract

Sixteen patients with essentialy hypertension were treated with propranolol 160 to 640 mg daily for three months. Significant decreases both in recumbent and standing blood pressure were observed after three days treatment and subsequently. Reduction of blood pressure was more pronounced when the dose of propranolol was increased. However, neither the mean dose nor the plasma concentration of propranolol could be correlated with the mean decrease in blood pressure. There was great interindividual variation in the plasma concentrations of propranolol produced by the same daily dose. The initial stimulation of plasma renin activity and the therapeutic response to propranolol could not be correlated.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 852494     DOI： 10.1007/BF00606403

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Drug therapy: Propranolol.

Authors:  D G Shand
Journal:  N Engl J Med       Date:  1975-08-07       Impact factor: 91.245

2.  Stimulated renin: a screening test for hypertension.

Authors:  L Wallach; I Nyarai; K G Dawson
Journal:  Ann Intern Med       Date:  1975-01       Impact factor: 25.391

3.  Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

Authors:  C A Chidsey; P Morselli; G Bianchetti; A Morganti; G Leonetti; A Zanchetti
Journal:  Circulation       Date:  1975-08       Impact factor: 29.690

Review 4.  Individualization of propranolol therapy.

Authors:  D G Shand
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

5.  Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response.

Authors:  L Hansson; A J Zweifler; S Julius; C N Ellis
Journal:  Int J Clin Pharmacol       Date:  1974-09

6.  Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension.

Authors:  F R Bühler; J H Laragh; E D Vaughan; H R Brunner; H Gavras; L Baer
Journal:  Am J Cardiol       Date:  1973-09-20       Impact factor: 2.778

7.  Propranolol in hypertension: a study of long-term therapy, 1964-1970.

Authors:  F J Zacharias; K J Cowen; J Prestt; J Vickers; B G Wall
Journal:  Am Heart J       Date:  1972-06       Impact factor: 4.749

8.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

9.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04

10.  Beta-blockers and plasma renin activity in hypertension.

Authors:  G S Stokes; M A Weber; I R Thornell
Journal:  Br Med J       Date:  1974-01-12
View more
  8 in total

1.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

2.  Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.

Authors:  T Baba; S Murabayashi; K Aoyagi; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Authors:  B Flouvat; I Berlin; A Cournot; D Robinet; J Duchier; H Sarmini; A Rossi
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

Review 4.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug.

Authors:  B Beermann; M Groschinsky-grind
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

6.  A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.

Authors:  T Ishizaki; Y Oyama; T Suganuma; T Sasaki; H Nakaya; T Shibuya; T Sato
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

7.  Relationship of propranolol pharmacokinetics to antihypertensive effect and beta-adrenergic blockade in the treatment of hypertension.

Authors:  R T Krediet; A J Dunning; L Offerhaus
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

8.  Correlation between propranolol in plasma and urine, renin-aldosterone system and blood pressure in essential hypertension.

Authors:  E B Pedersen; H J Kornerup; O L Pedersen; F Andreasen; P Bjerregaard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.